

A Complete Pharmacogenomic Clinical Support Tool to Help Guide Your Medication Decisions

BasePair Genomics (BPG) Pharmacogenomics Report is a test to determine how your patient's genetic profile effects the way they may respond to various medications.

The **BPG Report** aims to lessen the trial and error of prescribing by providing evidence-based, professionally guided medication alerts that are based on your patient's genetics. The test analyses fifteen genes, covering liver metabolism, as well as drug transporters and receptors.

Gene List

ABCB1, ABCC1, ABCG2, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, COMT, OPRM1, SLCO1B1, VKORC1 & UGT1A1.

The **BPG Pharmacogenomics Report** can help select the most appropriate medication for your patient, particularly if they are suffering from a chronic pain, mental illness or conditions associated with blood pressure, clotting, or following a stent procedure.

Drug Classes Reported

Anti-ADHD	Antiarrhythmics	Antifungal	Anticoagulants
Antidepressants	Anticonvulsant	Antidiabetics	Antiplatelet Agents
Antipsychotics	Antiemetics	Beta Blockers	Hypnotics
NSAIDs	Opioids	Protein Pump Inhibitors	SSRI's
Statins	Antiretroviral	Others	

BPG Pharmacogenomics Report has been found to be particularly useful for patients taking multiple medications, or those who have had medication failures or experienced significant side-effects. It can also be useful even before commencing medication, enabling the right medication selection for your patient, the first time.

The **BPG Pharmacogenomics Report** provides evidence-based, genetically guided medication alerts and recommendations from preeminent, expert international bodies, including the US Food and Drug Administration, the Clinical Pharmacogenomics Implementation Consortium, and the Dutch Pharmacogenomics Working Group.

The information contained in the **BPG Pharmacogenomics Report** is intended to be interpreted by a treating clinician. The report is not intended to take the place of professional medical advice. Decisions on the use of medications must be made only after consulting with the treating clinician and should consider the patient's medical history and current treatment regimen.

BasePair Genomics provides advanced genetic analysis and medication-management tools to assist treatment decisions, enabling optimal care. Our Australian laboratory is accredited for medical testing by NATA & the Royal College of Pathologists of Australasia.